Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityThe development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicCurrent Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral TherapyComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsCrystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding siteComplexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradationExtension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubilityPicomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl GroupA mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptaseHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateExcision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinaseA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityDB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOsExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesMolecular docking studies of marine diterpenes as inhibitors of wild-type and mutants HIV-1 reverse transcriptase.Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.Classification of anti-HIV compounds using counterpropagation artificial neural networks and decision trees.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Novel approaches to inhibiting HIV-1 replication.Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionPreclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl EthersSynthesis and biological evaluation of 2-thioxopyrimidin-4(1H)-one derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and IntegraseDesign, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities.Enhanced interrogation: emerging strategies for cell signaling inhibitionStructure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.Unveiling the roles of HBV polymerase for new antiviral strategiesDrug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.HIV-1 drug discovery: targeting folded RNA structures with branched peptides.The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.Clinically relevant drug-drug interactions between antiretrovirals and antifungals
P2860
Q24628212-495933FC-1436-4149-BE53-49EE09C9F7D9Q24655011-A276D974-E21B-41CE-8661-3579F28C1A23Q26750980-59CE0393-1979-49A0-8C8E-05C62D59ABF5Q26777448-0F643727-AD86-4EB0-A4B4-E4D2405960DCQ27660224-87CC159F-A5AD-45B2-BA41-783F7DDAC431Q27675888-3EBFDDD5-839A-43DF-A419-60A1B7C6CCC2Q27679282-08DB7AEC-3158-458E-9876-244B7009B42CQ27680431-02208D1B-F2C9-4A54-A9D8-DA04B4A8796AQ27683249-042563B2-A970-4B57-A53D-B2F4689D7753Q28250395-4B0E5148-FE38-4ACA-B385-B024832BEAE9Q28480614-C75CB7BD-2309-4F4F-B7C0-9CB97314A948Q28533996-95D47932-78EA-4E33-A69E-8A29CDB794CDQ28535401-27895B4F-C8DB-470E-BD19-F5614F405DADQ28540200-DF3237E8-5009-42CD-AB79-30DBB9F73319Q30355053-0D4563A7-A01F-444B-ADA0-287B6AC05163Q30363318-F63806A6-4349-42D7-9137-4D852994F3DCQ30578338-3CFB98F1-19B5-405B-A0FC-918CAF02598EQ31039195-F95B96B1-10BB-40A5-ACA9-8B88DA8F2C86Q33624190-92759386-019F-43AF-9384-6B3000551644Q33624690-7394EC2E-899E-4A19-B33C-C8AFACB2158BQ33630579-1AE3890C-61E3-4954-B979-5C01559F6B45Q33649797-0F0EADB8-6172-4E3E-94E5-FE12389D566BQ33797808-05CCFB6F-8420-4CDA-B28E-B449B8BC00D9Q33798031-D1BC2B02-09B4-45E9-BD60-8A8957B63554Q33900441-B7FED3F1-4F1B-4991-B870-A510E49B4FF1Q33907525-8FF21F73-2719-41C9-BA41-4991E8D5E2EFQ34282609-D2797383-B6E2-4674-98D0-B432AAC2B34CQ34519713-1F530B3A-9792-4144-A3D0-23A2B2F69F58Q34685500-1DD7E372-AB3E-4605-AFC2-4248BFDB8EEDQ34737547-DDB0BF8E-DBCF-4440-8DF7-5DEAF4B63C96Q34779869-F544F06D-E924-43EA-9E0C-2C4CC8F0695EQ35013490-805F8DD5-4655-4DED-A6D8-92BDFE76CF27Q35178569-27BE0EB2-8967-4A43-BF5A-53C05D30EB0BQ35228851-898A8D7B-0894-4293-98FE-41042B1B660FQ35243844-2FE4F0F9-ED4C-4110-8117-A8C8A07624BCQ35441503-1D474A5C-ACB7-4CF4-8F30-FFE81897025DQ35497950-B0B47DFE-A375-4C9D-9EC6-237BBA86F4A0Q35626292-E1EFAA51-8D03-4594-92B5-CA69F46A0B07Q35859896-4573E7FD-FE3A-4C89-B96A-ADBC5C9B7131Q35892563-F266448A-413D-4010-9C86-082AFF9A1277
P2860
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@ast
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@en
type
label
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@ast
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@en
prefLabel
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@ast
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@en
P1433
P1476
Non-nucleoside reverse transcr ...... the last 20 years (1989-2009).
@en
P2093
Marie-Pierre de Béthune
P356
10.1016/J.ANTIVIRAL.2009.09.008
P577
2009-09-23T00:00:00Z